Improvement of Cell-Based Phenotypic Drug Screening Methods and Securing a Competitive Advantage
First written in FY2016. 25 of 32 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues to improve its proprietary screening methods to secure future competitive advantages and generate new candidate compounds. - FY2026-H1RestatedAnnual report
「CBP501, the most advanced compound in our development pipeline, was obtained through our proprietary screening, or drug discovery, process.」
The company continues to generate CBP501 based on its proprietary screening and expand its follow-on pipeline through exploratory research. - FY2025-H1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research and development preparations to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues to generate new candidate compounds and expand its development pipeline based on its proprietary drug discovery research. - FY2024-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science. Among these compounds, we decided to advance CBT005 to preclinical trials, an early stage of development involving nonclinical studies required to compile the data needed for an application to commence clinical trials, and began preparations for them.」
The company continues to expand its follow-on pipeline through proprietary exploratory research and prepare CBT005 for preclinical trials. - FY2024-Q2AdvancedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science. Among these compounds, we decided to advance CBT005 to preclinical trials, an early stage of development involving nonclinical studies required to compile the data needed for an application to commence clinical trials, and began preparations for them.」
While continuing to explore new candidate compounds and expand our pipeline, the company decided to advance CBT005 to preclinical trials and began preparations. - FY2024-Q1RestatedAnnual report
「We are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues measures to generate new candidate compounds through exploratory research and expand its development pipeline. - FY2023RestatedAnnual report
「For exploratory research, we conduct screening using our proprietary drug screening method. To advance this research efficiently, we are working to improve our screening method and increase the potential to generate and obtain new drug candidate compounds.」
The company continues exploratory research aimed at generating and obtaining new candidate compounds by improving its proprietary screening method. - FY2023-Q3RestatedAnnual report
「CBP501, the most advanced compound in our development pipeline, was obtained through our proprietary screening, or drug discovery, process. It is a distinctive anticancer drug, or immune activator, that adjusts the regulatory functions of the protein calmodulin and exerts anticancer activity through multiple mechanisms, converting immunologically cold tumors, which have few T cells capable of attacking cancer, into immunologically hot tumors, in which T cells are present and can attack the cancer.」
The company continues to generate CBP501 based on its proprietary screening and conduct exploratory research for new candidate compounds. - FY2022RestatedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues measures to improve its proprietary drug screening method and secure a competitive advantage in the future. - FY2022-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues exploratory research targeting CBT005, CBP-A08, IDO/TDO inhibitors and other compounds, as well as expansion of its pipeline of new candidate compounds. - FY2022-Q2AdvancedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBT005 and CBP-A08, which were created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
In addition to the previously described CBP-A08 and IDO/TDO inhibitors, CBT005 was explicitly identified, showing the specific expansion of the pipeline for exploring and developing new candidate compounds. - FY2021RestatedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues to improve its proprietary screening method as a measure to secure a competitive advantage. - FY2021-Q3RestatedAnnual report
「CBP501, the most advanced compound in our development pipeline, was obtained through our proprietary screening, or drug discovery, process.」
The company continues to pursue a policy of developing CBP501 and other compounds based on its proprietary screening and conducting exploratory research for new candidate compounds. - FY2021-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBP-A08, which was created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues to generate new candidate compounds, including CBP-A08 and IDO/TDO inhibitors, through proprietary exploratory research and expand its development pipeline. - FY2021-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research to generate new candidate compounds and expand our development pipeline, including CBP-A08, which was created based on new insights obtained during their development, and IDO/TDO inhibitors being optimized through joint research with Shizuoka University of Art and Science.」
The company continues to generate new candidate compounds, including CBP-A08 and IDO/TDO inhibitors, through proprietary exploratory research and expand its development pipeline. - FY2020RestatedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues to further improve its proprietary screening method as a measure to secure a competitive advantage. - FY2020-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline for generating and developing new candidate compounds. - FY2020-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline of new candidate compounds. - FY2020-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, which was created based on new insights obtained during their development, and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline of new candidate compounds. - FY2019-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline of new candidate compounds. - FY2019-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds, including CBP-A08, and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline of new candidate compounds. - FY2019-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline of new candidate compounds. - FY2018-Q3RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline. - FY2018-Q2RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds and expand our development pipeline.」
The company continues exploratory research using its proprietary drug screening method and expansion of its pipeline. - FY2018-Q1AdvancedAnnual report
「During the cumulative first quarter, we also focused on optimizing a group of new candidate compounds following CBP501 and CBS9106, with a view to enhancing corporate value over the medium to long term. As a result, we obtained the new candidate compound CBP-A08. We will prepare for CBP-A08's preclinical trials in the near future while taking financial constraints and other factors into consideration.」
The company obtained the new candidate compound CBP-A08 and advanced to the stage of preparing for preclinical trials. - FY2017RestatedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues to improve its proprietary screening method focused on the behavior of living cells as a measure to secure a competitive advantage. - FY2017-Q3AdvancedAnnual report
「During the cumulative first 3 quarters, we also focused on optimizing a group of new candidate compounds following CBP501 and CBS9106, with a view to enhancing corporate value over the medium to long term. We aim to select the most promising candidate compound from this group during the fourth quarter and prepare for the commencement of future preclinical trials.」
The company advanced the optimization of candidate compound groups following CBP501 and CBS9106, setting specific milestones of selecting the leading candidate during the fourth quarter and preparing for future preclinical trials. - FY2017-Q1RestatedAnnual report
「In addition to advancing the development of these 2 candidate compounds, we are conducting exploratory research using our proprietary drug screening method to generate new candidate compounds and expand our development pipeline.」
The company continues exploratory research using its proprietary screening method and expansion of its pipeline. - FY2016First statedAnnual report
「We continue to further improve this screening method with the aim of securing a sustainable competitive advantage in this area.」
The company continues to improve its proprietary screening focused on the behavior of living cells as the basis for generating candidate compounds.